NOMOS Centre for Parliamentary Studies and Pharma Value have produced a special report on drug evaluation committees, namely the Technical Scientific Committee and the Pricing and Reimbursement Committee of AIFA from 2004 to 2021.
We are two consultancy agencies that engage daily in monitoring and analysing regulations so that they can be understood and used to improve the choices of pharmaceutical companies, citizens, patient associations, but also of the decision-makers themselves.
We made the regulations and compositions of the commissions available and analysed them by considering the elements for which the current policy-making system pays the most attention: competences, gender, method of appointment, transparency.
Our intention is to create an Archive of Commissions.
In fact, we believe that it can be a valuable tool, as well as a compendium to support the memory of those who had the responsibility of being a member of the Commissions evaluating drugs in terms of clinical efficacy and economic value, it will help to better understand and focus on the transformations and development of scientific thinking in terms of governance, regulation and economic evaluation of drugs.
With this work of ours, which is undoubtedly still incomplete and imperfect, we hope to have contributed to the dissemination of drug regulatory knowledge, in this case the rules on the appointment of the members of the two AIFA commissions, men and women called upon to make important choices for public health with great responsibility.
